Compare iShares MSCI South Korea ETF (EWY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Nuwellis Inc — how do they compare? iShares MSCI South Korea ETF trades at $178.33 (market cap $26.77B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares MSCI South Korea ETF is far larger — about 12168.2× Nuwellis Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Nuwellis Inc for 26 Days on average.
| EWY | NUWE | |
|---|---|---|
Market Cap | $26.77B | $2.20M |
Volume | 12,180,040 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $146.65 |
52-Week Low | $80.72 | $0.68 |
Typical Hold Time | 46 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) trades at $183.72, down 1.44% amid mixed technical signals with neutral overall momentum. The ETF faces pressure from rising oil prices and global bond yields impacting South Korean semiconductor stocks, though AI-driven demand provides underlying support. Recent volatility around the 7,000 KOSPI level reflects ongoing tension between technology sector strength and macroeconomic headwinds.
Outlook remains cautiously optimistic given South Korea's strong corporate earnings and AI infrastructure growth, but concentrated exposure to Samsung and SK hynix creates sensitivity to memory cycle fluctuations. Key risks include persistent inflation pressures and global semiconductor demand volatility that could challenge near-term performance despite long-term AI tailwinds.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
